GlassScriptPhysician profile
Maya Pramod Lele
NPI 1902249352
$2,940.62
in general payments reported to CMS, 2019-2025
22 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $23.54 · 2021: $436 · 2022: $274 · 2023: $124 · 2024: $516 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.22 |
| Education | $237.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $564.49 | 2019-2025 | Tezspire, Fasenra, Daliresp |
| Regeneron Healthcare Solutions, INC. | $505.26 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $459.32 | 2021-2025 | Nucala |
| Penumbra, INC. | $277.96 | 2021 | |
| Genzyme Corporation | $206.98 | 2024-2025 | |
| Amgen INC. | $147.71 | 2022-2025 | |
| Galderma Laboratories, L.P. | $142.10 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $116.74 | 2019 | |
| Octapharma USA, INC. | $91.98 | 2021 | |
| Ascendis Pharma Endocrinology INC | $66.74 | 2025 | Yorvipath |
| Lilly USA, LLC | $53.52 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $50.94 | 2025 | Cuvitru |
| Alk-Abello, INC | $42.38 | 2023 | Ragwitek, Odactra, Grastek |
| Greer Laboratories, INC. | $36.05 | 2023-2025 | Palforzia, Oralair |
| Mannkind Corporation | $30.97 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $30.79 | 2025 | Hizentra |
| Abbott Laboratories | $24.42 | 2025 | Freestyle Libre 3 |
| Kaleo, INC. | $23.17 | 2022 | |
| Sequel Med Tech, LLC | $22.89 | 2025 | Twiist |
| Shire North American Group INC | $18.15 | 2019 | |
| Antares Pharma, INC. | $15.14 | 2024 | Xyosted |
| Biocryst US Sales Co., LLC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Lele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.